Journal publication

 Parham    09 Sep 2017 : 01:38


Journal Publication

Google Scholar :::: PubMed :::: ResearchGate

Journal full-texts

Kaboli PJ, Ismail P*, Ling KH (2018) Molecular Modeling, Dynamics Simulations, and Binding Efficiency of Berberine Derivatives: A New Group of RAF Inhibitors for Cancer Treatment. PLoS ONE; 13(3): e0193941. doi:10.1371/journal.pone.0193941

[ISI Impact Factor (2016): 2.81 / Q1]

Kaboli PJ*, Bazrafkan M, Ismail P, Ling KH. (2017) Molecular modelling of berberine derivatives as inhibitors of human smoothened receptor and hedgehog signalling pathway using a newly developed algorithm on anti-cancer drugs. Recent Patents on Anti-cancer Drug Discovery;12(4):384–400. doi:10.2174/1574892812666170929131247.

[ISI Impact Factor (2016): 2.95 / Q2]

Jabbarzadeh Kaboli, P*, Rahmat, A*, Ismail, P, Ling, K-H (2015) MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacological Research; 97:104-21.

 [ISI Impact Factor (2015): 4.82 / Q1] [Citations: 60]

Jabbarzadeh Kaboli, P, Rahmat, A*, Ismail, P, Ling, K-H (2014) Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. European Journal of Pharmacology; 740:584-95.

[ISI Impact Factor (2016): 2.90 / Q2] [Citations: 57]

Journal ABSTRACTS, reports, LETTERS etc.

Kaboli, PJ, Ismail, P, and Ling, K-H (2017). Berberine Derivatives as Multi-Kinase Inhibitors of MAP Kinase and PI3K Pathways: Molecular Modelling, Molecular Dynamics Simulations, and in vitro Evaluation. FASEB J. 31: 671.12-671.12.

[ISI Impact Factor (2016): 5.50 / Q1] [Citations: 1]

Kaboli, PJ, Bazrafkan, M, Ismail, P, and Ling, K-H (2017). A Novel One-Click Automated Drug Discovery tool: A New Approach Based on Binding Efficiency Indices. FASEB J. 31: 818.7-818.7.

[ISI Impact Factor (2016): 5.50 / Q1] [Citations: 1]


Kaboli PJ, Ismail P*, Ling KH (Under Review) Anti-tumor Activity of Berberine as Inhibitor of EGFR, ERK1/2, P38 MAPK and AKT in MDA-MB231 and MCF-7 Breast Cancer Cells Using in Vitro and in Silico Studies. 

[ISI Impact Factor (2016): 2.59 / Q2]